Cabaletta's cash runway and planned BLA filing both land in early 2028

Cabaletta Bio has set out a timetable that ties its balance sheet closely to its first possible product filing. With its third-quarter results on 5 November 2026, the company reported $299.4m in cash and said this funds operations into the first quarter of 2028. That is the same quarter in which it plans to submit a Biologics License Application (BLA) to the US Food and Drug Administration for rese-cel, its CAR T candidate, in myositis. The material available does not describe any financing plans beyond that point.

The filing will rest on topline results from the RESET-Myositis pivotal cohort, expected in the second half of 2027. The cohort covers two forms of the disease: dermatomyositis and antisynthetase syndrome. Cabaletta also said a Type B meeting with the FDA, one of the formal sessions in which sponsors and the agency align on development plans, concluded that multi-year durability data from its earlier Phase 1/2 work can support the application alongside the new cohort.

The company flagged a possible route to a faster review. It said data in juvenile dermatomyositis might qualify it for a Priority Review Voucher. As general context, such vouchers can shorten the agency's review of a later application. Cabaletta did not provide details of how eligibility would be established in the information available, and the voucher is not confirmed.

Cabaletta has also opened a pivotal cohort in systemic sclerosis with interstitial lung disease, adding a third autoimmune area to the rese-cel programme. No data, enrolment targets or timelines for that cohort were given in the material reviewed.